BioSpace News Archive

Mesa Laboratories, Inc., a global leader in the design and manufacturing of life science tools and critical quality control solutions, announced the completed acquisition of GKE-GmbH’s sterilization indicators business and its accredited, independent testing lab SAL GmbH.

SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, announced a license and option agreement with Synaffix B.V., a Lonza company, to develop next-generation antibody-drug conjugates for the treatment of solid tumors.

Antiverse Ltd and GlobalBio, Inc. announced they will be extending their collaboration to advance immune checkpoint inhibitors in cancer therapy.

BeiGene, Ltd. announced the presentation of promising new data showcasing BeiGene’s robust, science-driven solid tumor portfolio of commercialized and pipeline medicines at the European Society for Medical Oncology Congress 2023.

Establishment Labs Holdings Inc. announced that the U.S. Food and Drug Administration has granted 510 clearance for the Motiva Flora® SmoothSilk® Tissue Expander.

Vivani Medical, Inc., an innovative, preclinical-stage biopharmaceutical company that develops novel, long-term drug implants, announced that it will present at the BIO Investor Forum at 2:00 p.m. PDT at the Hilton San Francisco Union Square on October 18, 2023.

Phanes Therapeutics, Inc. announced that it has entered into a clinical collaboration agreement with Merck to study PT886, its first-in-class bispecific antibody targeting claudin 18.2 and CD47, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas.

Modifi Biosciences, a leader in DNA modification as a novel approach to target cancer, announced the closing of $4.3 million in a second round of seed financing, bringing the total raised to date to $10.7 million.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, reported preclinical data highlighting the therapeutic potential in liquid and solid tumors of potent and selective heterobifunctional degraders of MDM2, including KT-253.

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that key data from the Phase 1/2a OASIS clinical trial were presented at The Retina Society 56th Annual Scientific Meeting.